Cellular therapies in preclinical and clinical islet transplantation: Mesenchymal stem cells

• Despite increasing experience with islet allotransplantation for type 1 diabetes worldwide, outcomes remain variable and unpredictable. Mesenchymal stem cells (MSCs) have been shown to positively affect islets and improve transplantation outcomes in animal models and in a few clinical trials. MSCs are easily isolated from multiple tissues and expanded through ex vivo culture with preservation of their self-renewal capacity. The safety and feasibility of using MSCs-based cellular treatments for different conditions including diabetes have been confirmed in many clinical trials. With the favorable characteristics of MSCs that include both anti-inflammatory and immunomodulatory properties, the research interest of utilizing MSCs for improvement of a different aspect of the islet transplant procedure is increasing. We summarize the current knowledge available from MSCs-based therapy in preclinical and clinical islet transplantation, focus on the advantage for the islets, and how to ensure progress in this aspect of research, and finally discuss remaining questions and future perspectives. © 2020 Elsevier Inc. All rights reserved.

Ämnesord

NATURVETENSKAP  -- Biologi -- Biokemi och molekylärbiologi (hsv//swe)

NATURAL SCIENCES  -- Biological Sciences -- Biochemistry and Molecular Biology (hsv//eng)

Nyckelord

Adult stem cells

Cellular therapy

Islet transplantation

Islets

Mesenchymal stem cells

Stromal cells

Type 1 diabetes

Publikations- och innehållstyp

vet (ämneskategori)

kap (ämneskategori)